Home / Publication / A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

刊物

Zilovertamab Vedotin 在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体

Author(s): Thijs J. Zweers, Jos Lommerse, Eline van Maanen, Manash S. Chatterjee

Year: 2024 年 10 月 22 日

Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value

网络研讨会

ToxStudio®: In silico tools to accelerate toxicology assessments

网络研讨会

Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management

案例研究

BioTechX US 2025

会议

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Zilovertamab Vedotin 在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体

Zilovertamab Vedotin 在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体

Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value

ToxStudio®: In silico tools to accelerate toxicology assessments

Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management

BioTechX US 2025

订阅时事通讯

快捷链接

解决方案

联系我们